Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment.

MLA

Gravell, Rachel, et al. “Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment.” Current Oncology, vol. 31, no. 10, Oct. 2024, pp. 6384–94. EBSCOhost, https://doi.org/10.3390/curroncol31100474.

APA

Gravell, R., Frood, R., Littlejohns, A., Casanova, N., Goody, R., Podesta, C., Albazaz, R., & Scarsbrook, A. (2024). Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment. Current Oncology, 31(10), 6384–6394. https://doi.org/10.3390/curroncol31100474

Chicago

Gravell, Rachel, Russell Frood, Anna Littlejohns, Nathalie Casanova, Rebecca Goody, Christine Podesta, Raneem Albazaz, and Andrew Scarsbrook. 2024. “Can Patient Characteristics and Pre-Treatment MRI Features Predict Survival After Stereotactic Ablative Radiotherapy (SABR) Treatment in Hepatocellular Carcinoma (HCC): Preliminary Assessment.” Current Oncology 31 (10): 6384–94. doi:10.3390/curroncol31100474.